Last checked at 31 Mar 2021 15:01
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Total Voting Rights Update
London, UK, 31 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 215,837,965 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.
The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
Tim Watts (CEO) Lucy Huntington-Bailey (Company Secretary and General Counsel) | +44 (0)191 511 8500 | ||
Peel Hunt LLP - Nominated Adviser & Joint Broker | +44 (0) 20 7148 8900 | ||
James Steel / Christopher Golden | |||
finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
Geoff Nash / Alice Lane / Matthew Radley | |||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Lianne Cawthorne | or shield@walbrookpr.com | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx